Search

Your search keyword '"Mirabet, Sonia"' showing total 7 results
Start Over Author "Mirabet, Sonia" Publication Year Range This year
7 results on '"Mirabet, Sonia"'

1. Prognosis after heart transplant in patients with hypertrophic and restrictive cardiomyopathy. A nationwide registry analysis

Author

González-Urbistondo, Francisco, Almenar-Bonet, Luis, Gómez-Bueno, Manuel, Crespo-Leiro, Marisa, González-Vílchez, Francisco, García-Cosío, María Dolores, López-Granados, Amador, Mirabet, Sonia, Martínez-Sellés, Manuel, Sobrino, José Manuel, Díez-López, Carles, Farrero, Marta, Díaz-Molina, Beatriz, Rábago, Gregorio, de la Fuente-Galán, Luis, Garrido-Bravo, Iris, Blasco-Peiró, María Teresa, García-Quintana, Antonio, and Vázquez de Prada, José Antonio

Published
2024
Full Text
View/download PDF

2. Pronóstico del trasplante cardiaco en pacientes con miocardiopatía hipertrófica y restrictiva. Análisis de un registro nacional

Author

González-Urbistondo, Francisco, Almenar-Bonet, Luis, Gómez-Bueno, Manuel, Crespo-Leiro, Marisa, González-Vílchez, Francisco, García-Cosío, María Dolores, López-Granados, Amador, Mirabet, Sonia, Martínez-Sellés, Manuel, Sobrino, José Manuel, Díez-López, Carles, Farrero, Marta, Díaz-Molina, Beatriz, Rábago, Gregorio, de la Fuente-Galán, Luis, Garrido-Bravo, Iris, Blasco-Peiró, María Teresa, García-Quintana, Antonio, and Vázquez de Prada, José Antonio

Published
2024
Full Text
View/download PDF

3. Review of the allocation criteria for heart transplant in Spain in 2023. SEC-Heart Failure Association/ONT/SECCE consensus document

Author

González-Costello, José, Pérez-Blanco, Alicia, Delgado-Jiménez, Juan, González-Vílchez, Francisco, Mirabet, Sonia, Sandoval, Elena, Cuenca-Castillo, José, Camino, Manuela, Segovia-Cubero, Javier, Sánchez-Salado, José Carlos, Pérez de la Sota, Enrique, Almenar-Bonet, Luis, Farrero, Marta, Zataraín, Eduardo, García-Cosío, María Dolores, Garrido, Iris, Barge-Caballero, Eduardo, Gómez-Bueno, Manuel, de Juan Bagudá, Javier, Manito-Lorite, Nicolás, López-Granados, Amador, García-Guereta, Luis, Blasco-Peiró, Teresa, Sarralde-Aguayo, José Aurelio, Sobrino-Márquez, Manuel, de la Fuente-Galán, Luis, Crespo-Leiro, María Generosa, Coll, Elisabeth, Gran-Ipiña, Ferrán, Díaz-Molina, Beatriz, Doñate, Lucía, Arribas-Leal, José María, Sánchez-Vicario, Félix, Atienza, Felipe, Rábago Juan-Aracil, Gregorio, García-Quintana, Antonio, Martínez-Alpuente, Itziar, Riesgo-Gil, Fernando, Hernández-Montfort, Jaime, Oliver-Juan, Eva, Sánchez-Rivas, Javier, Padilla-Martínez, María, Pérez-Villares, José Miguel, Miñambres, Eduardo, and Domínguez-Gil, Beatriz

Published
2024
Full Text
View/download PDF

4. Revisión de los criterios de distribución de trasplante cardiaco en España en 2023. Documento de consenso SEC-Asociación de Insuficiencia Cardiaca/ONT/SECCE

Author

González-Costello, José, Pérez-Blanco, Alicia, Delgado-Jiménez, Juan, González-Vílchez, Francisco, Mirabet, Sonia, Sandoval, Elena, Cuenca-Castillo, José, Camino, Manuela, Segovia-Cubero, Javier, Sánchez-Salado, José Carlos, Pérez de la Sota, Enrique, Almenar-Bonet, Luis, Farrero, Marta, Zataraín, Eduardo, García-Cosío, María Dolores, Garrido, Iris, Barge-Caballero, Eduardo, Gómez-Bueno, Manuel, de Juan Bagudá, Javier, Manito-Lorite, Nicolás, López-Granados, Amador, García-Guereta, Luis, Blasco-Peiró, Teresa, Sarralde-Aguayo, José Aurelio, Sobrino-Márquez, Manuel, de la Fuente-Galán, Luis, Crespo-Leiro, María Generosa, Coll, Elisabeth, Gran-Ipiña, Ferrán, Díaz-Molina, Beatriz, Doñate, Lucía, Arribas-Leal, José María, Sánchez-Vicario, Félix, Atienza, Felipe, Rábago Juan-Aracil, Gregorio, García-Quintana, Antonio, Martínez-Alpuente, Itziar, Riesgo-Gil, Fernando, Hernández-Montfort, Jaime, Oliver-Juan, Eva, Sánchez-Rivas, Javier, Padilla-Martínez, María, Pérez-Villares, José Miguel, Miñambres, Eduardo, and Domínguez-Gil, Beatriz

Published
2024
Full Text
View/download PDF

5. Colchicine in acutely decompensated heart failure: the COLICA trial.

Author

Pascual-Figal, Domingo, Núñez, Julio, Pérez-Martínez, Maria T, González-Juanatey, José Ramón, Taibo-Urquia, Mikel, Llàcer-Iborra, Pau, Delgado, Juan, Villar, Sandra, Mirabet, Sonia, Aimo, Alberto, Riquelme-Pérez, Alejandro, Anguita-Sánchez, Manuel, Martínez-Sellés, Manuel, Noguera-Velasco, Jose A, Ibáñez, Borja, and Bayés-Genís, Antoni

Subjects
BRAIN natriuretic factor, HEART failure, VENTRICULAR ejection fraction, C-reactive protein, COLCHICINE, CONFIDENCE intervals
Abstract

Background and Aims Acute heart failure (AHF) promotes inflammatory activation, which is associated with worse outcomes. Colchicine has proven effective in other cardiovascular conditions characterized by inflammatory activation, but has never been evaluated in the setting of AHF. Methods This multicenter, randomized, double-blind, and placebo-controlled trial included patients with AHF, requiring ≥40 mg of intravenous furosemide, regardless of their left ventricular ejection fraction (LVEF) and inpatient or outpatient setting. Patients were randomized within the first 24 h of presentation to receive either colchicine or placebo, with loading dose of 2 mg, followed by 0.5 mg every 12 h for 8 weeks. Results A total of 278 patients [median age 75 years, LVEF 40%, baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) 4262 pg/mL] were randomized to colchicine (n = 141) or placebo (n = 137). The primary endpoint, the time-averaged reduction in NT-proBNP levels at 8 weeks, did not differ between the colchicine group [−62.2%, 95% confidence interval (CI) −68.9% to −54.2%] and the placebo group (−62.1%, 95% CI −68.6% to −54.3%) (ratio of change 1.0). The reduction in inflammatory markers was significantly greater with colchicine: ratio of change 0.60 (P <.001) for C-reactive protein and 0.72 (P =.019) for interleukin-6. No differences were found in new worsening heart failure episodes (14.9% with colchicine vs. 16.8% with placebo, P =.698); however, the need for intravenous furosemide during follow-up was lower with colchicine (P =.043). Diarrhea was slightly more common with colchicine, but it did not result in differences in medication withdrawal (8.5% vs. 8.8%). Conclusions Colchicine was safe and effective in reducing inflammation in patients with AHF; however, colchicine and placebo exhibited comparable effects on reducing NT-proBNP and preventing new worsening heart failure events. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Colchicine in acute heart failure: Rationale and design of a randomized double‐blind placebo‐controlled trial (COLICA).

Author

Pascual‐Figal, Domingo, Núñez Villota, Julio, Pérez‐Martínez, Maria Teresa, González‐Juanatey, José Ramón, Taibo‐Urquía, Mikel, Llàcer Iborra, Pau, González‐Martín, Javier, Villar, Sandra, Soler, Meritxel, Mirabet, Sonia, Aimo, Alberto, Riquelme‐Pérez, Alejandro, Anguita Sánchez, Manuel, Martínez‐Sellés, Manuel, Sánchez, Pedro L., Ibáñez, Borja, Bayés‐Genís, Antoni, Martínez, Andrés Ramón, Pérez, Alejandro Riquelme, and Bravo, Iris Paula Garrido

Subjects
HEART failure, TREATMENT effectiveness, VENTRICULAR ejection fraction, GLOMERULAR filtration rate, COLCHICINE, PEPTIDES
Abstract

Aims: Heart failure (HF) elicits a pro‐inflammatory state, which is associated with impaired clinical outcomes, but no anti‐inflammatory therapies have demonstrated a clinical benefit yet. Inflammatory pathways related with the interleukin‐1 axis are overactivated during episodes of acute HF. Colchicine, an anti‐inflammatory drug with proven benefits in acute pericarditis and ischaemic heart disease, may target this inflammatory response. This study aims to assess the efficacy of colchicine in acute HF patients. Methods: COLICA is a multicentre, randomized, double‐blind, placebo‐controlled trial enrolling 278 patients across 12 sites. Patients presenting with acute HF, clinical evidence of congestion requiring ≥40 mg of intravenous furosemide and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) >900 pg/ml, are eligible for participation. Patients are enrolled irrespective of left ventricular ejection fraction, HF type (new‐onset or not) and setting (hospital or outpatient clinic). Patients are randomized 1:1 within the first 24 h of presentation to either placebo or colchicine, with an initial loading dose of 2 mg followed by 0.5 mg every 12 h for 8 weeks (reduced dose if <70 kg, >75 years old, or glomerular filtration rate <50 ml/min/1.73 m2). The primary efficacy endpoint is the time‐averaged proportional change in NT‐proBNP concentrations from baseline to week 8. Key secondary and exploratory outcomes include symptoms, diuretic use, worsening HF episodes, related biomarkers of cardiac stress and inflammation, total and cardiovascular readmissions, mortality and safety events. Conclusion: COLICA will be the first randomized trial testing the efficacy and safety of colchicine for acute HF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Resultados a corto y largo plazo tras trasplante cardíaco en pacientes con cardiopatías congénitas

Author

Molina, Marta, Roselló, Elena, Tauron, Manel, Tabilo, Juan F., Fernandez, Constanza, Gotsens, Carla, Pueblas, Exzequiel, Montiel, José, Casellas, Sandra, Irabien, Angela, Corominas, Laura, López, Laura, Mirabet, Sonia, and Ginel, Antonino

Abstract

La supervivencia y la necesidad de trasplante cardiaco en pacientes con cardiopatía congénita han aumentado. Este estudio tiene como objetivo conocer las características perioperatorias y la supervivencia a largo plazo de estos pacientes tras el trasplante y compararlas con las de pacientes con cardiopatías no congénitas.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results